SCHEMBL5558591

SCHEMBL5558591

CC(C)C[C@H](CC(=O)NOCc1ccccc1)C(=O)N[C@](C)(C(=O)NC(C)C(N)=O)c1ccc2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 9/20 0.43
MMP9 P14780 9/20 0.43
MMP8 P22894 8/20 0.43
MMP1 P03956 5/20 0.41
FCER2 P06734 3/20 0.41
PTPN1 P18031 2/20 0.39
ERAP2 Q6P179 1/20 0.37
ERAP1 Q9NZ08 1/20 0.37
LNPEP Q9UIQ6 1/20 0.37
MMP7 P09237 3/20 0.36
MMP12 P39900 1/20 0.36
MMP13 P45452 1/20 0.36
MMP3 P08254 2/20 0.35
CCR1 P32246 1/20 0.35
ECE1 P42892 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5556739 0.91 MMP2 (0.41) MMP2MMP9MMP8MMP1FCER2
SCHEMBL5556802 0.87 MMP2 (0.50) MMP2MMP9MMP8MMP1FCER2
SCHEMBL7370265 0.80 MMP1 (0.57) MMP2MMP9MMP8MMP1FCER2
SCHEMBL5552717 0.79 MMP1 (0.52) MMP2MMP9MMP8MMP1FCER2
SCHEMBL5558426 0.79 MMP1 (0.52) MMP2MMP9MMP8MMP1FCER2
SCHEMBL5552656 0.79 MMP9 (0.64) MMP2MMP9MMP8MMP1FCER2
SCHEMBL5557636 0.79 KDM4E (0.37) MMP2MMP9MMP8MMP1FCER2
SCHEMBL5557500 0.77 MMP2 (0.47) MMP2MMP9MMP8MMP1FCER2
SCHEMBL6245527 0.77 MMP2 (0.47) MMP2MMP9MMP8MMP1FCER2
SCHEMBL5552331 0.77 MMP2 (0.47) MMP2MMP9MMP8MMP1FCER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070197577-A1 Inhibitors of anthrax lethal factor CENGENT THERAPEUTICS (US) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197577-A1 Inhibitors of anthrax lethal factor APAF1, ANTXR2, LITAF MMP2 85/4885MMP9 182/4885MMP8 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.